

## ▶ GENERAL INFORMATION

### Location

Hof ter Musschen  
Av. Emmanuel Mounierlaan 2  
1200 Brussel  
Tel.: +32 (0) 2 774 01 10

### Target audience

The target audience for this symposium consists out of: hematologists, hematology nurses, hematologists in training and other physicians interested.

### Registration

Please register online via the BHS website ([www.bhs.be](http://www.bhs.be)), or via the calendar at [www.congresscare.com](http://www.congresscare.com)  
Registration is free of charge.

### Language

The meeting language will be English.

### Accreditation

Accreditation is pending.

### Website

[www.bhs.be](http://www.bhs.be)

## ▶ CONGRESS SECRETARIAT

Congress Care  Congress Care  
P.O. Box 440  
5201 AK 's-Hertogenbosch  
The Netherlands  
Tel +31 (0)73 690 14 15  
[bhs@congresscare.com](mailto:bhs@congresscare.com)  
[www.congresscare.com](http://www.congresscare.com)



## Symposium

Optimizing the use of novel agents in multiple myeloma: recommendations on how to prevent and manage adverse event

## ▶ Announcement



▶ **Friday 20 October 2017**  
Hof ter Musschen, Brussel

▶ [www.bhs.be](http://www.bhs.be)

## ▶ INTRODUCTION

The therapeutic landscape of multiple myeloma has dramatically changed over the last years and is still in continuous evolution. Second-generation proteasome inhibitors, new immunomodulatory drugs and monoclonal antibodies have improved the outcome of myeloma patients and can be given in various combinations at different stages of the disease.

Good knowledge on how to prevent and manage the side effects of these agents is crucial to maximize their therapeutic benefit and preserve the quality of life of patients.

We welcome physicians and nurses treating myeloma patients and those indirectly involved in myeloma care on this symposium dedicated to prevention and management of adverse events.

### COMMITTEE MEMBERS:

*Chairman: Michel Delforge*

Karolien Beel  
Greet Bries  
Jo Caers  
Bernard De Prijck  
Hade De Samblanx  
Michel Delforge  
Hilde Demuyne  
Anne Deweweire  
Chantal Doyen  
Caroline Jacqy  
Karel Fostier  
Alain Kentos

Nathalie Meuleman  
Philippe Mineur  
Fritz Offner  
Rik Schots  
Ann Van de Velde  
Jan Van Droogenbroeck  
Isabelle Vande Broek  
Mélanie Vaes  
Marie-Christiane Vekemans  
Philip Vlummens  
Kalung Wu

## ▶ PROGRAMME

### FRIDAY 20 OCTOBER 2017

Chairs: *Chantal Doyen en Michel Delforge*

15:00 - 15:10 Welcome

15:10 - 15:50 **Part 1: Immunomodulatory drugs**

15:10 2 case reports: *Dr. Isabelle Vandebroek (AZ Nikolaas), Prof. Marie-Christiane Vekemans (UCL, Saint-Luc)*

15:20 Presentation: *Prof. Nathalie Meuleman (Institut Jules Bordet)*

15:50 - 16:30 **Part 2: Proteasome inhibitors**

15:50 2 case reports: *Dr. Karel Fostier (UZ Brussel), Prof. Jo Caers (CHU de Liège)*

16:00 Presentation: *Prof. Michel Delforge (UZ Leuven)*

16:30 - 17:00 Coffee break

17:00 - 17:40 **Part 3: Monoclonal antibodies**

17:00 1 case report: *Dr. Philip Vlummens (UZ Gent)*

17:05 Presentation: *Dr. Niels Van de Donk (Vrije Universiteit Amsterdam, the Netherlands)*

17:40 - 18:10 **Part 4: Conventional drugs (steroids, chemo) and future agents**

Presentation: *Prof. Chantal Doyen (UCL, Mont-Godinne)*

18:10 - 18:15 Concluding remarks: *Prof. Michel Delforge*

18:15 - 18:45 Drinks